Ref: SPL/CORP-SEC/2020-21/BSE/1327

Dated: 13.02.2021

To,

Bombay Stock Exchange Ltd, Phirojshah Jeejobhoy Towers, 25th Floor, Dalal Street, Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting for the FY 2020-21 held on Saturday, 13th February 2021 with Scrip Code 524703.


A Meeting of the Board of Directors of the Company duly convened on Saturday, 13th February 2021 at 4:30 p.m. and Concluded at 8.00 p.m. at the Corporate Office of the Company at Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai 400071 inter alia, discussed the following business:-

- (a) It has approved Unaudited Financial Results for the Quarter ended $31^{\rm st}$ December 2020 along with Limited Review Report.
- (b) It has Re-appointed M/s Lalit Gawde & Associates, and Shri. Akhil Pai, Chartered Accountant as the Internal Auditor for the Financial year 2021-22.

You are requested to kindly take the same on record.

Yours Faithfully,

For Sandu Pharmaceuticals Limited







Sandu Pharmaceuticals Ltd

STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 31/12/20

(Rs in Lakhs)

DIN :- 01132141

Particulars 12-2020 99-2020 12-2019 31-12-2029 51-09-2020 31-09-2020		Quarter				Nine Months ended		(No III Lakiis)
Revenue From Operations		Particulars		Quarter Ended 30-		Nine months Ended	Nine months	Year Ended 31-03- 2020
1			Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total accorse (HI)		Revenue From Operations	1,576.88	1,722.15	1,318.04	4,466.00	3,735.08	4,836.75
Core		Other Income	7.19	6,69	13.05	16.26	41.01	45.2
Cost of materials consumed 325.08 304.85 248.11 821.73 633.15 913 Purchases of Stock-in-Trade 530.50 534.47 532.33 1,282.76 1,148.53 1,700 Changes in inventries of finished goods, 1,700 1,7	1	Total Income (I+II)	1,584.07	1,728.84	1,331.09	4,482.26	3,776.09	4,882.0
Purchasses of Stock-in-Trade	V	EXPENSES						
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress (44.50) 330.00 (80.59) 654.56 205.14 (10) Stock-in-Trade and work-in-progress (44.50) 330.00 (80.59) 654.56 205.14 (10) Stock-in-Trade and work-in-progress (44.50) 330.00 (80.59) 657.2 (33.19) 43.00 (80.59) 657.2 (33.19) 43.00 (80.59) 657.2 (33.19) 43.00 (80.59) 677.2 (33.19) 43.00 (80.59) 677.2 (33.1		Cost of materials consumed	325.08	304.65	246.11	821.73	633.15	913.8
Changes in invertories of finished goods,		Purchases of Stock-in-Trade	536.50	534.47	532.33	1,282.79	1,148.53	1,700.8
Stock-in-Trade and work-in-progress (44,50) 330,00 (80,59) 654,56 205,14 (10)		Changes in inventories of finished goods,						
Employee benefits expense			(44.50)	330.00	(80.59)	654.56	205.14	(103.3
Finance costs						100000000000000000000000000000000000000		685.1
Depreciation and amortization expense			1.39		0.101000	Turner 1		43.4
Other expenses (V) 1,130,13 1,494 Total expenses (V) 1,542,26 1,674,23 1,309,37 4,379,88 3,691,96 4,789 Profit/(loss) before exceptional items and 41,81 54,61 21,72 102,38 84,13 92 Exceptional items								55.2
Profit/(loss) before exceptional items and 41,81 54,61 21,72 102,38 84,13 92								1,494.7
Tax (0-NV) Tax		Total expenses (IV)	1,542.26	1,674.23	1,309.37	4,379.88	3,691.96	4,789.8
Tax (0-NV) Tax		Profit/(loss) before exceptional items and	41.81	54.61	21.72	102.38	84.13	92.1
	/		41.01	01.01				
	/1	(S.//Y.D.) (S.					0.44	0.2
(V-V)							0.44	0.2
Tax expense:	VII		41.91	E4 61	21.72	102.38	83.60	91.9
				34.01	21.12	102.30		91.4
(2) Deferred tax	/111	TOTAL STATE OF THE PARTY	12.28	44.05	E 00	28 93		12.6
(3) Short / Excess Provision (3) Short / Excess Provision (4) Profit (Loss) for the period from 29.33 39.67 15.63 72.80 69.89 72 (5) Continuing elevations (VII-VIII) (6) Profit (Joss) for the period (IX-XIII) 29.33 39.67 15.63 72.80 69.89 72 (7) Other Comprehensive Income	VIII							
Profit (Loss) for the period from			0.20	0.29	0.43	0.65		(,)
Continuing Serations (VII-VIII) Conter Comprehensive Income A (i) Items that will not be reclassified to profit or loss 23.74 7.87 3.26 46.29 5.16 (31 (ii) Income tax relating to items that will not be reclassified to profit or loss 8 (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss Control (iii) Income tax relating to items that will be reclassified to profit or loss Control (iii) Income tax relating to items that will be reclassified to profit or loss Control (iii) Income tax relating to items that will be reclassified to profit or loss Control (iii) Income tax relating to items that will be reclassified to profit or loss Control (iii) Income tax relating to items that will be reclassified to profit or loss Control (iii) Income tax relating to items that will be reclassified to profit or loss Control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income tax relating to items that will control (iii) Income								70.0
Column	X		29,33	39.67	15.63	72.80		72.0
Other Comprehensive Income		A DECEMBER OF THE PERSON OF TH					0.000	
A (i) Items that will not be reclassified to profit or loss 23.74 7.87 3.26 46.29 5.16 (31 (ii) Income tax relating to items that will not be reclassified to profit or loss (2.47) (0.82) (0.33) (4.81) (0.04) 3 (4.81) (0.04) 3 (6.81) (1.81)			29.33	39.67	15.63	72.80		72.0
profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss (iii) Income tax relating to items that will not be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit) (Loss) and Other Comprehensive Income for the period) Faid Up Equity Capital (Face Value of Rs. 1,0/- Per share) Total Comprehensive Income for the period) For Sandu Pharmaceuticals Ltd Mumbal: Umesh Sandu Umesh Sandu								•
(ii) Income tax relating to items that will			20.74					-
not be reclassified to profit or loss (2.47) (0.82) (0.33) (4.81) (0.04) 3 B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit) 50.60 46.72 18.56 114.28 75.01 44 (I (Loss) and Other Comprehensive Income for the period) Paid Up Equity Capital (Face Value of Rs. 10/- Per share) 708.10			23.74	7.87	3.26	46.29	5.16	(31.1
B (i) Items that will be reclassified to profit or loss					-			-
profit or loss			(2.47)	(0.82)	(0.33)	(4.81)		3.8
(ii) Income tax relating to items that will be reclassified to profit or loss - Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit) 50.60 46.72 18.56 114.28 75.01 44 (Loss) and Other Comprehensive Income for the period) - Paid Up Equity Capital (Face Value of Rs. 10/- Per share) 708.10 708								
De reclassified to profit or loss								
Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit) 50.60 46.72 18.56 114.28 75.01 44							•	
Period (XIII+XIV)(Comprising Profit) 50.60 46.72 18.56 114.28 75.01 44		The state of the s						
(Loss) and Other Comprehensive Income for the period) Paid Up Equity Capital (Face Value of Rs 10/- Per share) 708.10 708.						and the second		36
Paid Up Equity Capital (Face Value of Rs. 10/- Per share.) 708.10 7	XII	(Loss) and Other Comprehensive Income for the		46.72	18.56	114.28	75.01	44.7
(IV) (Face Value of Rs. 10/- Per share) 708.10 708.							-	
CVI Earnings per equity share (for continuing operation): (1) Basic 0.41 0.56 0.22 1.03 0.99 1 (2) Diluted 0.41 0.56 0.22 1.03 0.99 1	KIV		708 10	708.10	708.10	708.10		708.1
Operation :	XVI		100.10	100.10	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1,32,19	1.33.10	
(1) Basic 0.41 0.56 0.22 1.03 0.99 1 (2) Diluted 0.41 0.56 0.22 0.99 1 (2) Diluted 0.41 0.99 1 (2) Diluted 0.41 0.56 0.22 0.99 1 (2) Diluted 0.41 0.56 0.22 0.99 1 (2) Diluted 0.41 0.99 1 (2) Dilute								
(2) Diluted 0.41 0.56 0.22 1.03 0.99 1			0.44	n se	0.22	1.03	0.99	1.0
For Sandu Pharmaceuticals Ltd Mumbai: Umesh Šandu								1.0
Mumbai: Umesh Sandu			5,41	2.00				
municum						For Sandu Pharmaceuticals Ltd		
municum					Mon			3/9
		Mumbai:				Umesh Sandu		
						Managing	Director	90

- 1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 13th February 2021. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
- 2. The Company has considered the possible impact of COVID-19 pandemic on its operations, liquidity position and recoverability of its asset balances at 31st December, 2020 based on the internal and external information upto the date of approval of these financial results. The impact of COVID-19 may be different from that estimated as at the date of approval of these financial results and management will continue to monitor any material changes arising due to the impact of this pandemic on financial and operational performance of the Company and take necessary measures to address the situation.
- 3. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
- 4. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 13th February ,2021.there are no qualifications in the limited review report issued for the nine months & quarter ended December 2020.

5. Figures for the previous periods have been reclassified/regrouped, whenever necessary

Place: - Mumbai

Date: - 13/02/2021

For Sandu Pharmaceuticals Ltd

Umesh Sandu Managing Director

DIN: - 01132141



Dileep & Prithvi

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE UNAUDITED FINAICIAL RESULTS OF THE COMPANY FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2020, PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To,

The Board of Directors, Sandu Pharmaceuticals Limited, Plot No. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Bardez, Goa-403511.

Dear Sirs,

- 1. We have reviewed the accompanying Statement of Unaudited Financial Results of Sandu Pharmaceuticals Limited ("the Company") for the quarter and nine months ended on 31st Dec, 2020, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dileep & Prithvi

Chartered Accountants

Firm Registration Number: 122290W

Himmat Mali (Partner)

Membership Number: 183378 UDIN- 21183378AAAAAW6124 MUMBAI Regn. No.:- 53 122290W

Place: Mumbai Date: 13th February, 2021